These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 15534110

  • 21. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
    Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM.
    Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247
    [Abstract] [Full Text] [Related]

  • 22. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
    Xu Y, Yao L, Li H, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Larsson O, Xie Y.
    Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
    [Abstract] [Full Text] [Related]

  • 23. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
    Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Kawaguchi M, Miura Y, Iwase H.
    Clin Cancer Res; 2005 Jan 01; 11(1):193-8. PubMed ID: 15671546
    [Abstract] [Full Text] [Related]

  • 24. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun 01; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

  • 25. Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.
    Boorjian S, Tickoo SK, Mongan NP, Yu H, Bok D, Rando RR, Nanus DM, Scherr DS, Gudas LJ.
    Clin Cancer Res; 2004 May 15; 10(10):3429-37. PubMed ID: 15161698
    [Abstract] [Full Text] [Related]

  • 26. Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer.
    Yamamoto H, Horiuchi S, Adachi Y, Taniguchi H, Nosho K, Min Y, Imai K.
    Carcinogenesis; 2004 Mar 15; 25(3):325-32. PubMed ID: 14604892
    [Abstract] [Full Text] [Related]

  • 27. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
    Zhang H, Stephens LC, Kumar R.
    Clin Cancer Res; 2006 Mar 01; 12(5):1479-86. PubMed ID: 16533771
    [Abstract] [Full Text] [Related]

  • 28. [Clinical significance and relationship of expression of matrix metalloproteinase-2 mRNA with breast cancer metastasis].
    Xiao CH, Feng YM, Li XQ, Hao XS.
    Zhonghua Wai Ke Za Zhi; 2005 May 01; 43(9):599-604. PubMed ID: 15938935
    [Abstract] [Full Text] [Related]

  • 29. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
    Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C.
    Cancer; 2003 Aug 01; 98(3):474-83. PubMed ID: 12879463
    [Abstract] [Full Text] [Related]

  • 30. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases.
    Xie M, Sun Y, Li Y.
    Laryngoscope; 2004 Dec 01; 114(12):2243-8. PubMed ID: 15564854
    [Abstract] [Full Text] [Related]

  • 31. [Significance of membrane type-1 matrix metalloproteinase expression in breast cancer].
    Yao GY, Yang MT, Rong TH, He P.
    Ai Zheng; 2004 Nov 01; 23(11 Suppl):1482-6. PubMed ID: 15566663
    [Abstract] [Full Text] [Related]

  • 32. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma.
    Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MT, Bassarova A, Kvalheim G, Nesland JM, Reich R.
    Gynecol Oncol; 2006 Sep 01; 102(3):453-61. PubMed ID: 16494928
    [Abstract] [Full Text] [Related]

  • 33. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course.
    Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC, Hicks DG.
    Clin Cancer Res; 2005 Jan 01; 11(1):186-92. PubMed ID: 15671545
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
    Vasaturo F, Sallusti E, Gradilone A, Malacrino C, Nardo T, Avagnano G, Aglianò AM, Granato T, De Vincenzi B, Coppotelli G, Marzullo A, Soda G, Simonelli L, Modesti M, Scarpa S.
    Int J Oncol; 2005 Oct 01; 27(4):1005-11. PubMed ID: 16142317
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.